Prophase Labs, Inc. Announces That Testing Volumes Exceeded Well over 300,000 PCR COVID-19 Tests During Fourth Quarter 2021
January 13, 2022 at 06:45 pm IST
Share
ProPhase Labs, Inc. announced that testing volumes exceeded well over 300,000 PCR COVID-19 tests during Fourth Quarter 2021. These record results are significantly greater than the Company's previous record levels of approximately 110,000 tests performed in First Quarter 2021 due to growth in the Company's diversified and expanding customer base for testing services and increased demand for COVID-19 testing related to the emergence of the Omicron variant. The Company has significantly expanded headcount to over 250 laboratory professionals (up from approximately 50 laboratory professionals in the past quarter) to meet the increased demand for PCR COVID-19 testing.
This increase has facilitated the Company's return to testing results within 48 hours on average from the time of receipt.
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
PROPHASE LABS, INC. 
